Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company based in the United States. The company is primarily focused on developing NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is currently in Phase 2 clinical trials for patients with aggressive forms of non-muscle invasive bladder cancer. Additionally, Relmada is developing Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for potential treatments of Prader-Willi syndrome, Tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company also has agreements with Asarina Pharma AB and Trigone to support its development programs.

Relmada Therapeutics is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol RLMD. The trading currency for its shares is the US Dollar (USD). As a US-based company, its stock is traded in the United States, and investors typically transact in USD.

Relmada Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing novel therapies for medical conditions, including bladder cancer and neurological disorders. Biotechnology companies like Relmada are involved in research and development of drugs and treatments, often requiring significant investment and regulatory approvals before products can reach the market.

Relmada Therapeutics is headquartered in Coral Gables, Florida, United States. The company was founded in 2004, giving it over two decades of history in the biotechnology field. Its location in the US places it within a major market for healthcare innovation, and its operations are primarily focused on clinical development of its product candidates. The company serves the US market and collaborates with international partners such as Asarina Pharma AB and Trigone.